Hepatitis C Community
13.2k Members
Avatar universal

The risk of hep B reactivating in some patients being treated for hep C

The FDA published a memo dated 10-04-16 warning about the risk of hepatitis B becoming an active infection
again in any patient who has a current or previous infection with HBV and is being treated now for hep C. In a
few cases, HBV reactivation resulted in fulminant hepatitis, hepatic failure, need for a liver transplant and death.
Has anyone reading this ever experienced (who previously had hep B) problems while undergoing hep C
treatment?
2 Responses
683231 tn?1467326617
Risk of hepatitis B reactivation in patients treated with direct-acting antivirals for hepatitis C.
Aggeletopoulou I, et al. World J Gastroenterol. 2017.
Show full citation
Abstract
The recent introduction of direct-acting antiviral drugs (DAAs) for treatment of the hepatitis C virus (HCV) has greatly improved the management of HCV for infected patients. These viral protein inhibitors act rapidly, allowing HCV clearance and increasing the sustained virological response rates. However, hepatitis B virus (HBV) reactivation has been reported in HCV/HBV co-infected patients. Hepatitis B reactivation refers to an abrupt increase in the HBV and is well-documented in patients with previously undetected HBV DNA due to inactive or resolved HBV infection. Reactivation can occur spontaneously, but in most cases, it is triggered by various factors. Reactivation can be transient, without clinical symptoms; however, it usually causes a hepatitis flare. HBV reactivation may occur regardless of HCV genotype and type of DAA regimen. HBV screening is strongly recommended for co-infected HCV/HBV patients before initiation and during DAA therapy regardless of HBV status, HCV genotype and class of DAAs used. HBV reactivation can be prevented with pretreatment screening and prophylactic treatment when necessary. Additional data are required to evaluate the underlying mechanisms of HBV reactivation in this setting.

PMID 28706414 [PubMed - in process] PMCID PMC5487495
Full text
683231 tn?1467326617
I am on a couple of forums and so far haven’t see anyone report this happening to them. But of course it is a risk if you have a hep b infection

Also found this information

In general, how common is reactivation of HBV infection?

RG If a person is infected with HCV, is placed on HCV treatment, and is HBsAg-positive, the risk of HBV reactivation is very high (probably 30%-50%). If the patient is HBsAg-negative but hepatitis B core antibody (anti-HBc)-positive, the risk of reactivation is probably between 1:1000 and 1:10,000, although a recent publication suggested that the risk might be even slightly higher. That estimate comes from data collection by the US Food and Drug Administration (FDA) and my expert estimate of the total US patient population treated to date with DAA agents.

G&H What are the most common risk factors for HBV reactivation?

RG If a patient is undergoing chemotherapy or immunosuppression and is HBsAg-positive, especially if he or she is HBV DNA–positive, the patient is at moderate to high risk of reactivation, especially if (1) a regimen containing rituximab is used; (2) the patient undergoes conditioning therapy for stem-cell transplantation; (3) the patient is being treated with a doxorubicin-based chemotherapy; and (4) high-dose prednisone is used for a prolonged period of time, typically in combination with other immunosuppression. In my practice, I follow the rule that 20 mg or more of prednisone per day for more than 20 days would place a patient at moderate to high risk of reactivation if the patient is HBsAg-positive.

In patients who are HBsAg-negative but anti-HBc–positive, the risk of reactivation is lower but not zero, and rituximab-containing regimens might pose a reactivation risk as high as 30% in anti-HBc–positive patients, as well as in the other 3 settings listed above. Thus, the risk of reactivation depends upon the patient’s serostatus and HBV DNA status. Approximately 7% of anti-HBc–positive patients who are HBsAg-negative have measurable HBV DNA at low levels and may be at higher risk of reactivation than patients who are HBV DNA–negative by sensitive polymerase chain reaction assays. A technical review and guidelines for HBV reactivation during immunosuppressive therapy were published in the January 2015 issue of Gastroenterology.
Have an Answer?
Top Hepatitis Answerers
317787 tn?1473362051
DC
683231 tn?1467326617
Auburn, WA
Learn About Top Answerers
Hepatitis C Community
13.2k Members
48.6k Questions
Answer a few simple questions about your Hep C treatment journey.

Those who qualify may receive up to $100 for their time.
Explore More In Our Hep C Learning Center
image description
Learn about this treatable virus.
image description
Getting tested for this viral infection.
image description
3 key steps to getting on treatment.
image description
4 steps to getting on therapy.
image description
What you need to know about Hep C drugs.
image description
How the drugs might affect you.
image description
These tips may up your chances of a cure.
Popular Resources
How eating more salt may actually save your life.
A deeper look into the relationship between salt and hypertension.
Why checking at new times can help.
Could you benefit from this alternative glucose testing method?
They’re one of your most important tools for managing diabetes.
Learn about less common treatments for managing diabetes.